KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.

Xin Wang, Ouying Yan, Jitao Zhou, Feng Wen, Yali Shen, Zhiping Li, Qiu Li, Wenling Wang, Xiaohong Cai, Shisheng Tan, Zi Wang, Qing Qiao, Dan Cao, Meng Qiu, Jiyan Liu, Hongfeng Gou, Ming Liu, Cheng Yi, Yu Yang, Qing Zhu, Deyun Luo, Yaqin Zhao, Ye Chen, Shang Wang, Qiaoli Wang, Ke Cheng, Min Ren, Xin Liu, Feng Xu, Feng Bi

JAMA Netw Open 9(6) e2616154

PMID42295761
PMCIDPMC13270272
DOI10.1001/jamanetworkopen.2026.16154
发表日期2026-06-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

IMPORTANCE: Despite advances in D2 gastrectomy (ie, gastrectomy with D2 lymphadenectomy) and adjuvant chemotherapy, the value of adding postoperative radiotherapy (RT) to adjuvant chemotherapy after D2 gastrectomy remains a topic of ongoing debate. OBJECTIVE: To assess whether the addition of RT to the S-1 plus oxaliplatin (SOX) chemotherapy regimen increases disease-free survival (DFS) in patients with T4 or node-positive gastric cancer after D2 gastrectomy. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial was conducted between December 1, 2012, and August 30, 2022, at 5 large tertiary hospitals in China. Eligible patients were aged 18 to 70 years with gastric adenocarcinoma who underwent R0 resection with D2 lymphadenectomy, had pathologic stage T4 or node-positive disease, and had no evidence of metastasis (M0). Intention-to-treat statistical analyses were conducted from January 14 to March 31, 2025. INTERVENTIONS: Participants were assigned 1:1 to receive concurrent chemoradiotherapy (SOX RT) or chemotherapy alone (SOX). The SOX RT group received 1 cycle of induction SOX, followed by RT (50.4 Gy in 28 fractions) with concurrent S-1 (50 mg twice daily), and then 3 cycles of SOX. The SOX group received 6 cycles of SOX (S-1 30-40 mg/m2 twice daily on days 1-14; oxaliplatin 130 mg/m2 on day 1, every 3 weeks). MAIN OUTCOMES AND MEASURES: The primary end point was 3-year DFS. Secondary end points included overall survival (OS) and adverse events. RESULTS: A total of 620 patients were randomly assigned to the SOX group (n = 311) or SOX RT group (n = 309). Patients had a median (IQR) age of 55 (47-62) years and included 401 males (64.7%). Overall, 274 patients (44.2%) had T4 disease, and 590 (95.2%) had node-positive disease. In the primary analysis for the prespecified 3-year DFS end point, there was no evidence of a between-group difference in DFS (SOX RT vs SOX: HR, 0.98; 95% CI, 0.73-1.33). Similarly, there was no evidence of a between-group difference in OS (HR, 0.86; 95% CI, 0.60-1.23). The Kaplan-Meier-estimated 3-year DFS rates were 70.5% in the SOX RT group and 69.3% in the SOX group (log-rank P = .93), and the corresponding 3-year OS rates were 80.8% and 78.4%, respectively (log-rank P = .41). At 5 years, the DFS rates were 60.0% and 57.3% (log-rank P = .76) and the corresponding OS rates were 73.7% and 71.4% (log-rank P = .55) in the SOX RT and SOX groups, respectively. Treatment-related adverse events were similar between groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with T4 or node-positive gastric cancer who underwent D2 gastrectomy, SOX RT did not significantly improve DFS or OS. Accordingly, among patients with D2-resected gastric cancer, the findings do not support routine addition of adjuvant chemoradiotherapy to chemotherapy. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR-TRC-12002919.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Kaplan-Meier Curves for Disease-Free Survival (DFS) in the Intention-to-Treat Population Patients were randomized to receive S-1 plus oxaliplatin (SOX; n = 311) or SOX plus radiotherapy (SOX RT; n = 309) after D2 gastrectomy. Tick marks indicate censored observations. The dashed vertical line indicates 36 months. P value was calculated using a 2-sided log-rank test.

DFS

Disease-Free Survival

Figure 2 · Panel DFS

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 3

Figure 3.. Kaplan-Meier Curves for Overall Survival (OS) in the Intention-to-Treat Population Patients were randomized to receive S-1 plus oxaliplatin (SOX; n = 311) or SOX plus radiotherapy (SOX RT; n = 309) after D2 gastrectomy. Tick marks indicate censored observations. The dashed vertical line indicates 36 months. P value was calculated using a 2-sided log-rank test.

Overall_Survival_OS_

Overall Survival

Figure 3 · Panel Overall_Survival_OS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival_OS_ 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Trial Flow Diagram All randomized patients were included in the intention-to-treat (ITT) analysis. Receipt of the allocated intervention was defined as completion of the prespecified assigned treatment per protocol. SOX indicates S-1 plus oxaliplatin; SOX RT, SOX plus radiotherapy.
非 KM Figure
Figure 4Figure 4.. Dot Plot of Subgroup Analyses of Disease-Free Survival (DFS) Hazard ratios (HRs) and 95% CIs were estimated using unadjusted Cox proportional hazards regression models within each subgroup (treatment group as the only covariate). DFS follow-up was censored at 5 years for this subgroup analysis. P values for interaction were derived from Cox models that included a treatment-by-subgroup interaction term. HRs less than 1.0 indicate lower risk of disease recurrence or death with SOX plus radiotherapy (SOX RT) compared with S-1 plus oxaliplatin (SOX). Error bars represent 95% CIs. AJCC stage is derived from the seventh edition (2010) of the American Joint Committee on Cancer and Union for International Cancer Control staging criteria.
非 KM Figure